Arthneeti
JP

Jubilant Pharmova Ltd

Q4 FY24Pharmaceuticals & Biotechnology

Jubilant Pharmova Ltd Q4 FY24 Results & Presentation Highlights: Revenue, Margins & Order Book

Q4 FY24 investor presentation: what the company reported on revenue, margins and projects.

Price₹1,064
Market cap₹17.0K Cr
P/E43.7
Updated24 Sept 2026
Read4 min read

Based on Jubilant Pharmova Ltd's Q4 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q4 FY24 total revenue was Rs. Q4 FY24 EBITDA: Rs.

From Jubilant Pharmova Ltd's Q4 FY24 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

- Q4 FY24 total revenue was Rs. 1,759 Cr, a 5% YoY increase from Rs. 1,678 Cr in Q4 FY23. - Segment revenues (Q4 FY24 vs Q4 FY23, YoY growth): • Radiopharma: Rs. 818 Cr (+19%) • Radiopharmaceuticals: Rs. 256 Cr (+19%) • Radiopharmacies: Rs. 561 Cr (+18%) • Allergy Immunotherapy: Rs. 188 Cr (+11%) • CDMO Sterile Injectables: Rs. 259 Cr (-19%) • Generics: Rs. 201 Cr (+1%) • CRDMO: Rs. 282 Cr (-4%) - Radiopharmacy growth driven by volume increase from new products and operational efficiencies. - Allergy Immunotherapy growth supported by volume and price increases.

2 more points management made on revenue & sales performance

Profitability & Margins

See what Jubilant Pharmova Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • CDMO Sterile Injectables: Doubling Spokane capacity for sterile fill and finish (liquid and lyophilization) with a total investment of USD 285 Mn; partly funded by US Govt. cooperative agreement of USD 149.6 Mn.
  • Line 3 commercialization expected in FY26; Line 4 expected by FY28. (Page 30)
  • Radiopharmacy: Evaluating opportunity for PET radiopharmacy network expansion. (Page 19)
  • CDMO Sterile Injectable: Capacity expansion at Spokane on track; Line 3 commercial operations expected by Q1 FY26. (Page 52)

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Jubilant Pharmova Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided investor presentation (1660.pdf) does not report any information on order book, order inflow, or pending orders. None of the referenced pages (1-60) contain any data or statements regarding current order backlog, new orders received, or pending orders for the company. The presentation primarily focuses on: - Business segments and strategy (Radiopharmaceuticals, Allergy Immunotherapy, CDMO, CRDMO, Generics, Proprietary Novel Drugs) - Financial metrics, shareholding pattern, and sustainability initiatives

2 more points management made on order book & pipeline

Jubilant Pharmova Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹2.3K Cr, net profit ₹119 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Jubilant Pharmova Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Bharat Parenterals Ltd (Q4 FY24)

    For Q4 FY 2024, consolidated revenue from operations was INR 67.82 crore, up 13.4% YoY (Q4 FY 2023: INR 59.82 crore). Key investor presentation takeaways from B

  • Themis Medicare Ltd (Q4 FY24)

    97.82 Cr, up 22.11% YoY from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q4 FY24 investor presentation — and how it ranks against sector

  • Fermenta Biotech Ltd (Q4 FY24)

    Q4-FY24 Consolidated Operational Revenue: INR 973 Mn, down 7.5% YoY (Page 11) . Key investor presentation takeaways from Fermenta Biotech Ltd's Q4 FY24 investor

  • Amrutanjan Health Care Ltd (Q4 FY24)

    OTC: ₹108.37 Cr, up 27.57% YoY (Q4 FY23: ₹84.95 Cr) . Key investor presentation takeaways from Amrutanjan Health Care Ltd's Q4 FY24 investor presentation — and

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Jubilant Pharmova Ltd Q4 FY24 results?

Q4 FY24 total revenue was Rs. Q4 FY24 EBITDA: Rs.

What is Jubilant Pharmova Ltd share price analysis?

Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 43.7 with a market cap of ₹16,972 Cr. Investors should review the full earnings analysis for detailed insights.

Is Jubilant Pharmova Ltd planning capital expenditure?

CDMO Sterile Injectables: Doubling Spokane capacity for sterile fill and finish (liquid and lyophilization) with a total investment of USD 285 Mn; partly funded by US Govt.

Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.